DE69942095D1 - Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het - Google Patents

Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het

Info

Publication number
DE69942095D1
DE69942095D1 DE69942095T DE69942095T DE69942095D1 DE 69942095 D1 DE69942095 D1 DE 69942095D1 DE 69942095 T DE69942095 T DE 69942095T DE 69942095 T DE69942095 T DE 69942095T DE 69942095 D1 DE69942095 D1 DE 69942095D1
Authority
DE
Germany
Prior art keywords
het
protein
preparation
treatment
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942095T
Other languages
English (en)
Inventor
Gregoire Prevost
Marie-Odile Lonchampt
Thomas Gordon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Application granted granted Critical
Publication of DE69942095D1 publication Critical patent/DE69942095D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
DE69942095T 1998-07-08 1999-07-05 Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het Expired - Lifetime DE69942095D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9808731A FR2780974B1 (fr) 1998-07-08 1998-07-08 Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
PCT/FR1999/001609 WO2000002881A2 (fr) 1998-07-08 1999-07-05 Utilisation de derives de la cysteine pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimerique

Publications (1)

Publication Number Publication Date
DE69942095D1 true DE69942095D1 (de) 2010-04-15

Family

ID=9528405

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942095T Expired - Lifetime DE69942095D1 (de) 1998-07-08 1999-07-05 Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het

Country Status (17)

Country Link
US (3) US6544995B1 (de)
EP (1) EP1100801B1 (de)
JP (1) JP2002520327A (de)
AR (1) AR019908A1 (de)
AT (1) ATE459625T1 (de)
AU (1) AU756268B2 (de)
CA (1) CA2336846C (de)
DE (1) DE69942095D1 (de)
ES (1) ES2341404T3 (de)
FR (1) FR2780974B1 (de)
MY (1) MY122419A (de)
NO (1) NO319633B1 (de)
NZ (1) NZ509789A (de)
RU (1) RU2268889C2 (de)
TW (1) TW561156B (de)
WO (1) WO2000002881A2 (de)
ZA (1) ZA200101061B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
US7084135B1 (en) 1998-12-31 2006-08-01 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Prenyl transferase inhibitors
WO2000039130A2 (en) 1998-12-31 2000-07-06 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Prenyl transferase inhibitors
DE10164711A1 (de) * 2001-03-13 2002-10-17 Schebo Biotech Ag Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren und/oder Aminosäureanalogen zur Modulation des Glycolyse-Enzym-Komplexes, des Malat Aspartat Shuttles und/oder der Transaminasen
DE10112925A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren, Aminosäureanalogen zur Modulation von Transaminasen und/oder der Assoziation p36/Malat Dehydrogenase
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US20060052382A1 (en) * 2002-12-20 2006-03-09 Duffy Joseph L 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
FR2921658A1 (fr) * 2007-09-27 2009-04-03 Sod Conseils Rech Applic Derives des pyrazolo-pyrazines comme inhibiteurs de proteines g
CN101824036A (zh) * 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
JO3156B1 (ar) 2009-07-09 2017-09-20 Novartis Ag ايميدازولات مدمجة والتركيبات التي تشملها لعلاج الأمراض الطفيلية على مثال الملاريا
TWI791515B (zh) 2017-04-24 2023-02-11 瑞士商諾華公司 治療療法
CN112480122B (zh) * 2020-11-24 2022-03-22 中山大学 一种四氢咪唑[1,2-a]吡嗪类化合物、组合物及其制备方法与应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2080172A1 (en) * 1991-10-11 1993-04-12 Scott A. Biller Method for blocking neoplastic transformation of cells induced by ras oncogenes
GB9226065D0 (en) * 1992-12-14 1993-02-10 Ici Plc Peptides
US5705686A (en) * 1993-05-18 1998-01-06 University Of Pittsburgh Inhibition of farnesyl transferase
WO1995000497A1 (en) * 1993-06-18 1995-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1995030012A1 (en) * 1994-04-26 1995-11-09 Cadus Pharmaceutical Corporation Functional expression of mammalian adenylyl cyclase in yeast
CA2159850A1 (en) * 1994-11-03 1996-05-04 Yadagiri Pendri Phosphonosulfonate squalene synthetase inhibitor salts and method
CA2207252C (en) * 1995-01-12 2014-02-25 University Of Pittsburgh Inhibitors of prenyl transferases
FR2736638B1 (fr) * 1995-07-12 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
CA2251716A1 (en) * 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
US5935812A (en) * 1996-09-18 1999-08-10 Incyte Pharmaceuticals, Inc. Human GTP binding protein gamma-3
RU2201931C2 (ru) * 1996-11-20 2003-04-10 Биомежер Инкорпорэйтед Ингибиторы фарнезилтрансферазы и способы ингибирования фарнезилтрансферазы
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique

Also Published As

Publication number Publication date
CA2336846A1 (en) 2000-01-20
EP1100801B1 (de) 2010-03-03
RU2268889C2 (ru) 2006-01-27
ATE459625T1 (de) 2010-03-15
US20060035899A1 (en) 2006-02-16
AR019908A1 (es) 2002-03-20
FR2780974B1 (fr) 2001-09-28
CA2336846C (en) 2010-03-16
ES2341404T3 (es) 2010-06-18
NO319633B1 (no) 2005-09-05
US20030162786A1 (en) 2003-08-28
US7034025B2 (en) 2006-04-25
EP1100801A2 (de) 2001-05-23
TW561156B (en) 2003-11-11
FR2780974A1 (fr) 2000-01-14
MY122419A (en) 2006-04-29
AU4622299A (en) 2000-02-01
NO20010029L (no) 2001-01-08
US6544995B1 (en) 2003-04-08
JP2002520327A (ja) 2002-07-09
NO20010029D0 (no) 2001-01-03
WO2000002881A2 (fr) 2000-01-20
NZ509789A (en) 2004-01-30
WO2000002881A3 (fr) 2000-03-16
ZA200101061B (en) 2002-10-02
AU756268B2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE248599T1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE69942095D1 (de) Anwendung von cystein-derivaten zur herstellung eines arzneimittels bestimmt zur behandlung von pathologien hervorgehend aus entstehung der protein g het
DE60119283D1 (de) Verfahren zur herstellung von 3-hydroxypicolinsäure-derivaten
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE602006008641D1 (de) Herstellung und anwendung von tetrahydropyrrolo ä3, 2-cüpyridin-4-onderivaten zur behandlung von obesitas und psychiatrischen und neurologischen erkrankungen
DE50112916D1 (de) Verfahren zur herstellung von alkylarylsulfonaten
DE50100160D1 (de) Herstellung von aminofunktionellen Siloxanen
DE60142487D1 (de) Verfahren zur herstellung von liposomen
DE60119896D1 (de) Verwendung von pramipexol zur behandlung von tabak/nikotin abhängigkeit
DE60141788D1 (de) Verfahren zur Herstellung von epsilon-Caprolactam
DE60021963D1 (de) Verfahren zur Herstellung von Celluloseether
DE60112431D1 (de) Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments
DE60113943D1 (de) Verfahren zur Herstellung von porösem Polymid
DE60117106D1 (de) Verfahren zur Herstellung von Halopropyldimethylchlorosilanen
ATE232378T1 (de) Reinigungspflaster zur verbesserung des hautzustandes
DE60100858D1 (de) Prozess zur herstellung der kristallinen form i von cabergolin
DE60104244D1 (de) Verfahren zur Herstellung von Amiden
DE60122704D1 (de) Herstellung von iminodiessigsäure-derivaten aus monoethanolamin-substraten
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE60001015D1 (de) Verfahren zur Herstellung von Canthaxanthin
DE60028816D1 (de) Herstellung von unipolaren Komponenten
DE60230629D1 (de) Verwendung von 2,5-dihydroxybenzolsulfonsäure-derivaten bei der herstellung eines medikaments zur verstärkung der wirkung anderer arzneimittel zur behandlung der erektilen dysfunktion
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE69901243T2 (de) Artikulator zur herstellung von zahnärztlichen prothesen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition